Oncotarget

Research Papers:

Restoring microenvironmental redox and pH homeostasis inhibits neoplastic cell growth and migration: therapeutic efficacy of esomeprazole plus sulfasalazine on 3-MCA-induced sarcoma

Enrica Balza, Patrizia Castellani, Paola Sanchez Moreno, Patrizia Piccioli, Iria Medrano-Fernandez, Claudia Semino and Anna Rubartelli _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:67482-67496. https://doi.org/10.18632/oncotarget.18713

Metrics: PDF 676 views  |   HTML 1082 views  |   ?  


Abstract

Enrica Balza1,*, Patrizia Castellani1,*, Paola Sanchez Moreno1,3, Patrizia Piccioli1, Iria Medraño-Fernandez2, Claudia Semino2 and Anna Rubartelli1

1Cell Biology Unit, IRCCS AOU San Martino – IST, 16132 Genoa, Italy

2Protein Transport Unit, Division of Cell and Molecular Biology, San Raffaele Institute, 20132 Milan, Italy

3Present address: Nanobiointeractions and Nanodiagnostics, Istituto Italiano di Tecnologia, 16163 Genoa, Italy

*These authors have contributed equally to this work

Correspondence to:

Anna Rubartelli, email: anna.rubartelli@hsanmartino.it

Keywords: anti-oxidants, 3-methylcholanthrene-induced tumorigenesis, proton pump inhibitors, tumor-associated macrophages, xCT

Received: January 27, 2017    Accepted: May 22, 2017    Published: June 27, 2017

ABSTRACT

Neoplastic cells live in a stressful context and survive thanks to their ability to overcome stress. Thus, tumor cell responses to stress are potential therapeutic targets. We selected two such responses in melanoma and sarcoma cells: the xc- antioxidant system, that opposes oxidative stress, and surface v-ATPases that counteract the low pHi by extruding protons, and targeted them with the xc- blocker sulfasalazine and the proton pump inhibitor esomeprazole. Sulfasalazine inhibited the cystine/cysteine redox cycle and esomeprazole decreased pHi while increasing pHe in tumor cell lines. Although the single treatment with either drug slightly inhibited cell proliferation and motility, the association of sulfasalazine and esomeprazole powerfully decreased sarcoma and melanoma growth and migration. In the 3-methylcholanthrene (3-MCA)-induced sarcoma model, the combined therapy strongly reduced the tumor burden and increased the survival time: notably, 22 % of double-treated mice recovered and survived off therapy. Tumor-associated macrophages (TAM) displaying M2 markers, that abundantly infiltrate sarcoma and melanoma, overexpress xc- and membrane v-ATPases and were drastically decreased in tumors from mice undergone the combined therapy. Thus, the double targeting of tumor cells and macrophages by sulfasalazine and esomeprazole has a double therapeutic effect, as decreasing TAM infiltration deprives tumor cells of a crucial allied. Sulfasalazine and esomeprazole may therefore display unexpected therapeutic values, especially in case of hard-to-treat cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18713